These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 36229873)

  • 1. Neomorphic DNA-binding enables tumor-specific therapeutic gene expression in fusion-addicted childhood sarcoma.
    Hölting TLB; Cidre-Aranaz F; Matzek D; Popper B; Jacobi SJ; Funk CM; Geyer FH; Li J; Piseddu I; Cadilha BL; Ledderose S; Zwilling J; Ohmura S; Anz D; Künkele A; Klauschen F; Grünewald TGP; Knott MML
    Mol Cancer; 2022 Oct; 21(1):199. PubMed ID: 36229873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ablation of EWS-FLI1 by USP9X inhibition suppresses cancer cell growth in Ewing sarcoma.
    Wang S; Huo X; Yang Y; Mo Y; Kollipara RK; Kittler R
    Cancer Lett; 2023 Jan; 552():215984. PubMed ID: 36330954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective inhibition of HDAC6 regulates expression of the oncogenic driver EWSR1-FLI1 through the EWSR1 promoter in Ewing sarcoma.
    García-Domínguez DJ; Hajji N; Sánchez-Molina S; Figuerola-Bou E; de Pablos RM; Espinosa-Oliva AM; Andrés-León E; Terrón-Camero LC; Flores-Campos R; Pascual-Pasto G; Robles MJ; Machado I; Llombart-Bosch A; Magagnoli G; Scotlandi K; Carcaboso ÁM; Mora J; de Álava E; Hontecillas-Prieto L
    Oncogene; 2021 Sep; 40(39):5843-5853. PubMed ID: 34345016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability.
    He T; Surdez D; Rantala JK; Haapa-Paananen S; Ban J; Kauer M; Tomazou E; Fey V; Alonso J; Kovar H; Delattre O; Iljin K
    Gene; 2017 Jan; 596():137-146. PubMed ID: 27760381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EWS-FLI1 regulates a transcriptional program in cooperation with Foxq1 in mouse Ewing sarcoma.
    Shimizu R; Tanaka M; Tsutsumi S; Aburatani H; Yamazaki Y; Homme M; Kitagawa Y; Nakamura T
    Cancer Sci; 2018 Sep; 109(9):2907-2918. PubMed ID: 29945296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteasomal Degradation of the EWS-FLI1 Fusion Protein Is Regulated by a Single Lysine Residue.
    Gierisch ME; Pfistner F; Lopez-Garcia LA; Harder L; Schäfer BW; Niggli FK
    J Biol Chem; 2016 Dec; 291(52):26922-26933. PubMed ID: 27875302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the undruggable: exploiting neomorphic features of fusion oncoproteins in childhood sarcomas for innovative therapies.
    Knott MML; Hölting TLB; Ohmura S; Kirchner T; Cidre-Aranaz F; Grünewald TGP
    Cancer Metastasis Rev; 2019 Dec; 38(4):625-642. PubMed ID: 31970591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
    Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
    Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic targeting the oncogenic driver EWSR1::FLI1 in Ewing sarcoma through inhibition of the FACT complex.
    Mo J; Tan K; Dong Y; Lu W; Liu F; Mei Y; Huang H; Zhao K; Lv Z; Ye Y; Tang Y
    Oncogene; 2023 Jan; 42(1):11-25. PubMed ID: 36357572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of HDACs reduces Ewing sarcoma tumor growth through EWS-FLI1 protein destabilization.
    Pedot G; Marques JG; Ambühl PP; Wachtel M; Kasper S; Ngo QA; Niggli FK; Schäfer BW
    Neoplasia; 2022 May; 27():100784. PubMed ID: 35366465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EWS/FLI1 Characterization, Activation, Repression, Target Genes and Therapeutic Opportunities in Ewing Sarcoma.
    Yasir M; Park J; Chun W
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
    Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
    Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.
    Giorgi C; Boro A; Rechfeld F; Lopez-Garcia LA; Gierisch ME; Schäfer BW; Niggli FK
    Oncotarget; 2015 Oct; 6(30):28895-910. PubMed ID: 26336820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncofusion-driven de novo enhancer assembly promotes malignancy in Ewing sarcoma via aberrant expression of the stereociliary protein LOXHD1.
    Deng Q; Natesan R; Cidre-Aranaz F; Arif S; Liu Y; Rasool RU; Wang P; Mitchell-Velasquez E; Das CK; Vinca E; Cramer Z; Grohar PJ; Chou M; Kumar-Sinha C; Weber K; Eisinger-Mathason TSK; Grillet N; Grünewald TGP; Asangani IA
    Cell Rep; 2022 Jun; 39(11):110971. PubMed ID: 35705030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-specific retargeting of an oncogenic transcription factor chimera results in dysregulation of chromatin and transcription.
    Patel M; Simon JM; Iglesia MD; Wu SB; McFadden AW; Lieb JD; Davis IJ
    Genome Res; 2012 Feb; 22(2):259-70. PubMed ID: 22086061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.
    Tang SW; Bilke S; Cao L; Murai J; Sousa FG; Yamade M; Rajapakse V; Varma S; Helman LJ; Khan J; Meltzer PS; Pommier Y
    Clin Cancer Res; 2015 Sep; 21(18):4184-93. PubMed ID: 25779942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Druggable Rheostat for Ewing Sarcoma?
    Weiss KR; Bailey KM
    Clin Cancer Res; 2022 Oct; 28(20):4360-4362. PubMed ID: 35921177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic modeling optimizes inhibition of the 'undruggable' EWS-FLI1 transcription factor in Ewing Sarcoma.
    Hong SH; Youbi SE; Hong SP; Kallakury B; Monroe P; Erkizan HV; Barber-Rotenberg JS; Houghton P; Üren A; Toretsky JA
    Oncotarget; 2014 Jan; 5(2):338-50. PubMed ID: 24481407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor.
    Franzetti GA; Laud-Duval K; Bellanger D; Stern MH; Sastre-Garau X; Delattre O
    Oncogene; 2013 Aug; 32(33):3915-21. PubMed ID: 22986530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis.
    Showpnil IA; Miller KR; Taslim C; Pishas KI; Lessnick SL; Theisen ER
    J Vis Exp; 2020 Jun; (160):. PubMed ID: 32658189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.